Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP II (Ancrod Stroke Program)
2005-006067-31Phase 3Terminated
- Sponsor
- Neurobiological Technologies, Inc.
- Start
- May 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Ancrod (Viprinex) with Placebo (2 arms). Primary endpoint: Functional disability at Day 90. Started May 2006; status: terminated.
02
Drugs
ancrod
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2005-006067-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006067-31.